![](/img/cover-not-exists.png)
Comparing the Cost Effectiveness of Risperidone and Olanzapine in the Treatment of Schizophrenia Using the Net-Benefit Regression Approach
Annemieke De Ridder,Diana De GraeveVolume:
27
Language:
english
Journal:
PharmacoEconomics
DOI:
10.2165/00019053-200927010-00007
Date:
January, 2009
File:
PDF, 164 KB
english, 2009